Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
CNBC's Meg Tirrell reports on President Trump's attacks on Merck's CEO Ken Frazier after he left the WH Manufacturing Council.
The president may want to check his "facts" on Merck, which he accused of "taking jobs out of the U.S."
CNBC's Meg Tirrell reports on Bristol-Myers falling after its kidney cancer drug trial results. Also, more on Merck's CEO's decision to leave the President's manufacturing council.
After Merck CEO Ken Frazier announced his resignation from the president's manufacturing council, CNBC's Meg Tirrell reports on Frazier's previous fights for justice.
Frazier said the experience showed him "why there can be no fair and consistent application of the death penalty under the current system."
CNBC's Meg Tirrell discusses the biotech sector's worst day since January and what is driving the dip. The “Fast Money” traders weigh in.
CNBC's Meg Tirrell speaks with Chip Davis, Association for Accessible Medicines president, about generic drugs facing pricing pressures.
CEO Heather Bresch clarified on a call with investors that delaying Advair's launch to 2018 was due to the Food and Drug Administration reorganizing.
Jonathan Silverstein, OrbiMed and Silverstein Foundation, discusses how his foundation is working to develop drugs to cure Parkinson’s disease.